ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025
A randomized trial of narrow band imaging for performing airway mucosal biopsy in pulmonary sarcoidosis (NABS).
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05311150 (A Randomized Control Trial to Compare the Diagnostic Yield of Endobronchial Biopsy Performed Under Direct Narrow Band Imaging or White Light Bronchoscopy Guidance in Suspected Sarcoidosis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Control Trial to Compare the Diagnostic Yield of Endobronchial Biopsy Performed Under Direct Narrow Band Imaging or White Light Bronchoscopy Guidance in Suspected Sarcoidosis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundData suggest that narrow band imaging (NBI) highlights airway mucosal nodules better than white light bronchoscopy (WLB) in sarcoidosis. No randomized trial has compared the diagnostic yield of endobronchial biopsy (EBB) performed using NBI versus WLB.
methodsWe performed an investigator-initiated single-center, parallel-arm, randomized trial. Consecutive subjects ≥18 years of age with clinico-radiologic presentation consistent with sarcoidosis were randomised 1:1 to undergo EBB using NBI plus WLB (intervention) or WLB (control). OUTCOMES: The primary outcome was the diagnostic yield of EBB defined by finding of granulomas on pathologic examination in subjects with final diagnosed with sarcoidosis. The secondary outcomes included procedure duration and complications.
resultsWe included 150 (mean age, 43.1 years; 53.3% men) subjects; 75 each were assigned to either study group. Sarcoidosis was diagnosed in 126/150 subjects (66 and 60 in the NBI plus WLB and WLB groups, respectively). There was no difference (p=0.53) in the diagnostic yield of EBB between the NBI plus WLB (25/66, 37.9%) and the WLB (26/60, 43.3%) groups. Transbronchial lung biopsy and endobronchial ultrasound-guided transbronchial needle aspiration yielded granulomas in 69 of 115 (60%) and 68 of 98 (69.4%) subjects, who underwent these additional procedures, respectively. In 11 of the 14 (78.6%) cases, where WLB demonstrated airway nodules, NBI enhanced visualization. Moreover, it identified nodules in five additional cases. There were no between-group differences in the procedure duration or complications.
conclusionsThe use of NBI did not improve the yield of EBB in patients with sarcoidosis. Additional research is warranted. (Clinicaltrials.gov: NCT05311150).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.